Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression

Cancer Cell

Volumn 19, Issue 1, 2011, Pages 72-85

  DuPage, Michel ^a   Cheung, Ann F ^a   Mazumdar, Claire ^a   Winslow, Monte M ^a   Bronson, Roderick ^b   Schmidt, Leah M ^a   Crowley, Denise ^a   Chen, Jianzhu ^a   Jacks, Tyler ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; LUNG ADENOCARCINOMA; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 78651451436     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2010.11.011     Document Type: Article

References (53)

1. Bai A., Higham E., Eisen H.N., Wittrup K.D., Chen J. Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. Proc. Natl. Acad. Sci. USA 2008, 105:13003-13008.
2. Buckanovich R.J., Facciabene A., Kim S., Benencia F., Sasaroli D., Balint K., Katsaros D., O'Brien-Jenkins A., Gimotty P.A., Coukos G. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat. Med. 2008, 14:28-36.
3. Bucks C.M., Norton J.A., Boesteanu A.C., Mueller Y.M., Katsikis P.D. Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion. J. Immunol. 2009, 182:6697-6708.
4. Budhu A., Forgues M., Ye Q.H., Jia H.L., He P., Zanetti K.A., Kammula U.S., Chen Y., Qin L.X., Tang Z.Y., Wang X.W. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006, 10:99-111.
5. Calzascia T., Pellegrini M., Hall H., Sabbagh L., Ono N., Elford A.R., Mak T.W., Ohashi P.S. TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. J. Clin. Invest. 2007, 117:3833-3845.
6. Cheung A.F., Dupage M.J., Dong H.K., Chen J., Jacks T. Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. Cancer Res. 2008, 68:9459-9468.
7. Clark C.E., Hingorani S.R., Mick R., Combs C., Tuveson D.A., Vonderheide R.H. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007, 67:9518-9527.
8. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., Sougnez C., Greulich H., Muzny D.M., Morgan M.B., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
9. Drake C.G., Doody A.D., Mihalyo M.A., Huang C.T., Kelleher E., Ravi S., Hipkiss E.L., Flies D.B., Kennedy E.P., Long M., et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005, 7:239-249.
10. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3:991-998.
11. DuPage M., Dooley A.L., Jacks T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 2009, 4:1064-1072.
12. Ercolini A.M., Ladle B.H., Manning E.A., Pfannenstiel L.W., Armstrong T.D., Machiels J.P., Bieler J.G., Emens L.A., Reilly R.T., Jaffee E.M. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J. Exp. Med. 2005, 201:1591-1602.
13. Finak G., Bertos N., Pepin F., Sadekova S., Souleimanova M., Zhao H., Chen H., Omeroglu G., Meterissian S., Omeroglu A., et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 2008, 14:518-527.
14. Finn O.J. Immunological weapons acquired early in life win battles with cancer late in life. J. Immunol. 2008, 181:1589-1592.
15. Frese K.K., Tuveson D.A. Maximizing mouse cancer models. Nat. Rev. Cancer 2007, 7:645-658.
16. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., Tosolini M., Camus M., Berger A., Wind P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
17. Getnet D., Maris C.H., Hipkiss E.L., Grosso J.F., Harris T.J., Yen H.R., Bruno T.C., Wada S., Adler A., Georgantas R.W., et al. Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells. J. Immunol. 2009, 182:4675-4685.
18. Hanson H.L., Donermeyer D.L., Ikeda H., White J.M., Shankaran V., Old L.J., Shiku H., Schreiber R.D., Allen P.M. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 2000, 13:265-276.
19. Huijbers I.J., Krimpenfort P., Chomez P., van der Valk M.A., Song J.Y., Inderberg-Suso E.M., Schmitt-Verhulst A.M., Berns A., Van den Eynde B.J. An inducible mouse model of melanoma expressing a defined tumor antigen. Cancer Res. 2006, 66:3278-3286.
20. Jackson E.L., Willis N., Mercer K., Bronson R.T., Crowley D., Montoya R., Jacks T., Tuveson D.A. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001, 15:3243-3248.
21. Jackson E.L., Olive K.P., Tuveson D.A., Bronson R., Crowley D., Brown M., Jacks T. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 2005, 65:10280-10288.
22. Khong H.T., Restifo N.P. Natural selection of tumor variants in the generation of " tumor escape" phenotypes. Nat. Immunol. 2002, 3:999-1005.
23. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., Smyth M.J., Schreiber R.D. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450:903-907.
24. Lyman M.A., Aung S., Biggs J.A., Sherman L.A. A spontaneously arising pancreatic tumor does not promote the differentiation of naive CD8+ T lymphocytes into effector CTL. J. Immunol. 2004, 172:6558-6567.
25. Molldrem J.J., Lee P.P., Wang C., Felio K., Kantarjian H.M., Champlin R.E., Davis M.M. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 2000, 6:1018-1023.
26. Mueller S.N., Ahmed R. High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc. Natl. Acad. Sci. USA 2009, 106:8623-8628.
27. Muller-Hermelink N., Braumuller H., Pichler B., Wieder T., Mailhammer R., Schaak K., Ghoreschi K., Yazdi A., Haubner R., Sander C.A., et al. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 2008, 13:507-518.
28. Nguyen L.T., Elford A.R., Murakami K., Garza K.M., Schoenberger S.P., Odermatt B., Speiser D.E., Ohashi P.S. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J. Exp. Med. 2002, 195:423-435.
29. Novellino L., Castelli C., Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. 2005, 54:187-207.
30. Ochsenbein A.F., Sierro S., Odermatt B., Pericin M., Karrer U., Hermans J., Hemmi S., Hengartner H., Zinkernagel R.M. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001, 411:1058-1064.
31. Pages F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., Mlecnik B., Kirilovsky A., Nilsson M., Damotte D., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 2005, 353:2654-2666.
32. Parmiani G., De Filippo A., Novellino L., Castelli C. Unique human tumor antigens: immunobiology and use in clinical trials. J. Immunol. 2007, 178:1975-1979.
33. Pellegrini M., Calzascia T., Elford A.R., Shahinian A., Lin A.E., Dissanayake D., Dhanji S., Nguyen L.T., Gronski M.A., Morre M., et al. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat. Med. 2009, 15:528-536.
34. Piersma S.J., Jordanova E.S., van Poelgeest M.I., Kwappenberg K.M., van der Hulst J.M., Drijfhout J.W., Melief C.J., Kenter G.G., Fleuren G.J., Offringa R., van der Burg S.H. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007, 67:354-361.
35. Redmond W.L., Sherman L.A. Peripheral tolerance of CD8 T lymphocytes. Immunity 2005, 22:275-284.
36. Rubio V., Stuge T.B., Singh N., Betts M.R., Weber J.S., Roederer M., Lee P.P. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat. Med. 2003, 9:1377-1382.
37. Savage P.A., Vosseller K., Kang C., Larimore K., Riedel E., Wojnoonski K., Jungbluth A.A., Allison J.P. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science 2008, 319:215-220.
38. Schreiber H. Tumor immunology. Fundamental Immunology 2003, 1557-1592. Lippincott Williams & Wilkins, Philadelphia. W.E. Paul (Ed.).
39. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 2008, 8:247-258.
40. Segal N.H., Parsons D.W., Peggs K.S., Velculescu V., Kinzler K.W., Vogelstein B., Allison J.P. Epitope landscape in breast and colorectal cancer. Cancer Res. 2008, 68:889-892.
41. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., Schreiber R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111.
42. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
43. Smith K.M., Olson D.C., Hirose R., Hanahan D. Pancreatic gene expression in rare cells of thymic medulla: evidence for functional contribution to T cell tolerance. Int. Immunol. 1997, 9:1355-1365.
44. Speiser D.E., Miranda R., Zakarian A., Bachmann M.F., McKall-Faienza K., Odermatt B., Hanahan D., Zinkernagel R.M., Ohashi P.S. Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 1997, 186:645-653.
45. Spiotto M.T., Rowley D.A., Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat. Med. 2004, 10:294-298.
46. Spiotto M.T., Yu P., Rowley D.A., Nishimura M.I., Meredith S.C., Gajewski T.F., Fu Y.X., Schreiber H. Increasing tumor antigen expression overcomes " ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 2002, 17:737-747.
47. Street S.E., Trapani J.A., MacGregor D., Smyth M.J. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J. Exp. Med. 2002, 196:129-134.
48. Thomas D.A., Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005, 8:369-380.
49. Uyttenhove C., Maryanski J., Boon T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 1983, 157:1040-1052.
50. Ward P.L., Koeppen H.K., Hurteau T., Rowley D.A., Schreiber H. Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance. Cancer Res. 1990, 50:3851-3858.
51. Wherry E.J., Ha S.J., Kaech S.M., Haining W.N., Sarkar S., Kalia V., Subramaniam S., Blattman J.N., Barber D.L., Ahmed R. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007, 27:670-684.
52. Willimsky G., Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005, 437:141-146.
53. Zhou G., Lu Z., McCadden J.D., Levitsky H.I., Marson A.L. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J. Exp. Med. 2004, 200:1581-1592.